Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project

Cancer

Volumn 119, Issue 20, 2013, Pages 3662-3671

  Evens, Andrew M ^a   Vanderplas, Ann ^b   Lacasce, Ann S ^c   Crosby, Allison L ^c   Nademanee, Auayporn P ^b   Kaminski, Mark S ^d   Abel, Gregory A ^c   Millenson, Michael ^e   Czuczman, Myron S ^f   Rodriguez, Maria A ^g   Niland, Joyce ^b   Zelenetz, Andrew D ^h   Gordon, Leo I ⁱ   Friedberg, Jonathan W ^j  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

allogeneic transplantation; autologous transplantation; follicular lymphoma; non Hodgkin lymphoma; prognostication; rituximab; stem cell transplantation; survival

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; RITUXIMAB;

ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; FAILURE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; WHOLE BODY RADIATION;

ALLOGENEIC TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; FOLLICULAR LYMPHOMA; NON-HODGKIN LYMPHOMA; PROGNOSTICATION; RITUXIMAB; STEM CELL TRANSPLANTATION; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84885176407     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28243     Document Type: Article

References (25)

1. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000; 11: 1585-1590. (Pubitemid 32104758)
2. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25: 2554-2559. (Pubitemid 47044812)
3. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003; 21: 3918-3927. (Pubitemid 46606204)
4. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001; 97: 404-409. (Pubitemid 32060325)
5. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M,. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104: 18-28.
6. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184-4190.
7. Tomblyn MR, Ewell M, Bredeson C, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011; 17: 1051-1057.
8. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012; 119: 2093-2099.
9. LaCasce AS, Kho ME, Friedberg JW, et al. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008; 26: 5107-5112.
10. Klein JP, Moeschberger ML,. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag; 2003.
11. Marubini E, Valsecchi MG,. Analysing Survival Data from Clinical Trials and Observational Studies. New York, NY: John Wiley & Sons; 1995.
12. Gray R,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
13. Rosenbaum PR, Rubin DB,. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984; 79: 516-524.
14. Austin PC,. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27: 2037-2049. (Pubitemid 351772300)
15. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008; 26: 3614-3620.
16. Akhtar S, Maghfoor I,. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 6261.
17. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 4561-4566. (Pubitemid 41185123)
18. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008; 26: 3166-3175.
19. Pettengell R, Schmidtz N, Gisselbrecht C, et al. European Group for Blood and Marrow Transplantation. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol. 2010; 28 (15 suppl): abstract 8005.
20. Jacobson CA, Longo DL,. Follicular lymphoma: to treat or not to treat is no longer the question. J Natl Cancer Inst. 2012; 104: 3-5.
21. Le Gouill S, De Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011; 96: 1128-1135.
22. Kang TY, Rybicki LA, Bolwell BJ, et al. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant. 2007; 40: 973-978. (Pubitemid 350048196)
23. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008; 111: 5530-5536.
24. Pinana JL, Martino R, Gayoso J, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010; 95: 1176-1182.
25. Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010; 28: 3695-3700.